IDAP, the IFPMA’s vision of innovation development and access pathways

The International Federation of Pharmaceutical Manufacturers and Associations proposed the IDAP (Innovation Development and Access Pathway) framework to streamline and, as far as possible, harmonise pathways for ensuring rapid authorisation and access to innovative medicines and vaccines, taking into account the specific characteristics of different countries.

EU Life Sciences Strategy, comments to the call for evidence

The call for evidence closed on 17 April, and the proposal of the draft EU Life Sciences Strategy is expected by Q2 2025. It should encompass all the different industrial sectors in which life sciences play a central role for R&D and competitiveness, including pharmaceuticals, biotech and medtech